Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.

| Name |
|---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is...
Benzinga Rankings give you vital metrics on any stock – anytime.
You can purchase shares of Mesoblast (NASDAQ:MESO) through any online brokerage.
Other companies in Mesoblast’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Mesoblast has a consensus price target of $25.50.
The stock price for Mesoblast (NASDAQ: MESO) is $14.29 last updated October 9, 2026 at 4:00 PM EDT.
There are no upcoming dividends for Mesoblast.
Mesoblast does not have any upcoming earnings scheduled.
There is no upcoming split for Mesoblast.
Mesoblast is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.